More research is needed to better define the mutational landscape of EGFR and its dynamic biologic effects in HNSCC as a means to tailor EGFR-targeted therapies and thus enhance the clinical benefit derived from these therapies. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.